ReviewFrontiers in medicine2017
Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.Respiratory research · 2020Trial
- Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.Respiratory research · 2020Trial
- "Good health" and care needs in idiopathic pulmonary fibrosis/progressive pulmonary fibrosis: the COCOS-IPF patient-led European focus groups.ERJ open research · 2026Article
- Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Health-related quality of life in a multiracial Asian interstitial lung disease cohort.Journal of thoracic disease · 2022Article
- Application of Machine Learning to Improve Appropriateness of Treatment in an Orthopaedic Setting of Personalized Medicine.Journal of personalized medicine · 2022Article
- Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?Frontiers in medicine · 2021Review
- Early referral to palliative care in IPF - pitfalls and opportunities in clinical trials.Respiratory research · 2020Article
- "Right-to-Try" experimental drugs: an overview.Journal of translational medicine · 2020Review
- Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study.Breathe (Sheffield, England) · 2019Article
- Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis.Journal of personalized medicine · 2019Article
- The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.Respiratory research · 2019Article
- Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials.BMJ open respiratory research · 2018Article
- Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.Respiration; international review of thoracic diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease which has a major impact on patients' quality of life (QOL). Except for lung transplantation, there is no curative treatment option. Fortunately, two disease-modifying drugs that slow down disease decline were recently approved. Though this is a major step forward, these drugs do not halt or reverse the disease, nor convincingly improve health-related QOL. In daily practice, disease behavior and response to therapy greatly vary among patients. It is assumed that this is related to the multiple biological pathways and complex interactions between genetic, molecular, and environmental factors that are involved in the pathogenesis of IPF. Recently, research in IPF has therefore started to focus on developing targeted therapy through identifying genetic risk factors and biomarkers. In this rapidly evolving field of personalized medicine, patient factors such as lifestyle, comorbidities, preferences, and experiences with medication should not be overlooked. This review describes recent insights and methods on how to integrate patient perspectives into personalized medicine. Furthermore, it provides an overview of the most used patient-reported outcome measures in IPF, to facilitate choices for both researchers and clinicians when incorporating the patient voice in their research and care. To enhance truly personalized treatment in IPF, biology should be combined with patient perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.